Follicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
|
|
- Curtis Maxwell
- 5 years ago
- Views:
Transcription
1 Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona
2 Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie
3 FL remains an incurable disease, but new therapies improved survival Swedish registry, n = 2641 IOSI, Novara, Barcelona, London database, n = 1002 Junlén et al. Leukemia 2015 Conconi A, et al. Leuk Lymphoma. 2010
4 Patients progressing within 2 years have a bad prognosis Lymphocare study data (USA) 90% 50% (at 5 years) 588 patients: RCHOP no maintenance Prevalence early POD (2 years): 19% Casulo et al. J Clin Oncol 2015
5 FLIPI = Follicular Lymphoma International Prognostic Index 0-1 factor 2 factors AGE < 60 vs. 60 HEMOGLOBIN 12g/dL vs. < 12g/dL SERUM LDH LEVEL ULN vs. > ULN ANN ARBOR STAGE I II vs. III IV NUMBER OF NODAL SITES INVOLVED 4 vs. > factors Solal-Celigny, Blood 2004
6 The clinicogenetic risk model m7-flipi m7flipi High-risk FLIPI High-risk m7flipi High-risk FLIPI High-risk Pastore et al., Lancet Oncol., 2015
7 ESMO guidelines 2016 (simplified) Low tumor burden High tumor burden Stage I-II Stage III-IV Stage III-IV (age > 65) Stage III-IV (age < 65) Front line IF-RT W+W R- chemo + R- maintenance (W+W) (R-mono) (R-mono) Relapse W + W R-monotherapy R-chemo + maintenance Idelalisib Radioimmunotherapy Palliative RT SAME as >65 + HDCT with ASCT Allo-transplant Dreyling et al, Ann. Oncol. 2016
8 Relapse after RT: NCCN centres Stage Size of bulk Stage Size of bulk Charpentier et al., Abstr. 62, ICML-12, 2013
9 How to define high tumour burden patients? GELA criteria High tumor bulk defined by either: - a tumor > 7 cm - 3 nodes in 3 distinct areas each > 3 cm - symptomatic splenic enlargement - organ compression - ascites or pleural effusion Presence of systemic symptoms Serum LDH or β2-microglobulin above normal values BNLI criteria Rapid disease progression in the preceding 3 months Life threatening organ involvement Renal or liver infiltration Bone lesions Systemic symptoms or pruritus Hb<10 g/dl or WBC< /L or Plat.< /L ; related to marrow involvement
10 W+W does not compromise patients survival W+W vs. ProMACE-MOPP 89 pts Young, 1988 Overall survival W+W vs. Prednimustine 130 pts Brice, 1997 W+W vs. Chlorambucil 309 pts Ardeshna, 2003 With permission from The Lancet, Ardeshna K M et al., The Lancet, August 2003, Vol ):
11 Probability RT and CT have long-term life threatening side-effects HL: Competing Causes of Mortality Hodgkin s s Disease Second Malignancy Infection Cardiac/Pulmonary Other Years Diehl et al. Lancet Oncol 2004
12 Today 90% of FL aged <40 are alive at 10 years The median survival of FL patients aged < 40 is expected to be > 30 years! N= 155/1002, 4 EU centres N= 164/2652, Lymphocare Conconi et al. Ann Oncol 2015 Casulo et al. Ann Oncol 2015
13 Does waiting increase the chance of transformation? Al Tourah et al., JCO, 2008
14 Meta-analysis of chemo vs R-chemo: Overall survival Schulz H, et al. J Natl Cancer Inst 2007; 99:
15 Chemotherapy for FL: «is more better»? Ardeshna et al, The Lancet 2003 Peterson et al., JCO 2003 Sebban et al, Blood, 2006 Ladetto, M. et al. Blood 2008
16 Italian randomised study (N = 504) Is R-CHOP standard? No difference in OS! R-CHOP vs R-CVP R-FM vs R-CVP R-CHOP vs R-FM Federico M, et al. J Clin Oncol 2013 Mar 25. Epub ahead of print.
17 FL: STIL vs BRIGHT study (PFS) Time (months) Rummel MJ, et al. Lancet Flinn IW et al. ASH 2012; abstract 902.
18 FL Grading < 15 Cb/HPF 1 3a 3b 2 > 15 Cb/HPF All Cb/follicular LBCL/follicular 1-2 3a 3b LBCL = large B-cell lymphoma Images courtesy of Stefano A Pileri, MD
19 Overall Survival (%) Overall survival (%) Grade IS a predictive factor: Nebraska Follicular lymphoma mean counts No adriamycin p < Grade 1 Grade 2 Grade Years Follicular lymphoma mean counts Adriamycin p = 0.87 Grade 1 Grade 3 Grade Years Grade 3 FL must be treated with an anthracyclinecontaining regimen Nathwani BN, et al. Follicular lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). IARC Press: Lyon 2001.
20 Overall survival Overall survival Grade 3A vs 3B is a predictive factor: Nordic group Overall survival Grade 3B Grade 3A Time (years) Grade Grade 3A with anthra Grade 3B no anthra Time (years) Grade 3B with anthra Grade 1 2 no anthra Grade 1 2 with anthra Grade 3A no anthra Wahlin BE, et al. Br J Haemtaol 2012; 156:
21 Single agent R is a possible option RR of prolonged rituximab in first-line FL Colombat 2001 (n= 50) 73% Hainsworth 2002 (n= 60) 73% Witzig 2005 (n= 37) 72% Ghielmini 2005 (n= 202) 75% Kimby 2008 (n= 123) 78% Ardeshna 2010 (n= 192) 85%
22 Probability The response to upfront R can be longlasting EFS PFS Median EFS = 4.4 years 0.8 Median PFS = 7.4 years year years 1 year month Median EFS = 2.5 years Prolonged Standard p = Median PFS = 3.5 years P= Years since start of treatment Time from randomisation (years) Martinelli, J Clin Oncol 2010 Taverna C, J Clin Oncol 2015
23 R-maintanance: the PRIMA trial 3 years FU 6 years FU Rituximab maintenance 75% 59% Rituximab maintenance Observation 89% 87% Observation Stratified HR = % CI: p < % 43% Time (months) Patients at risk p = Time (months) Salles G, et al. Lancet 2011; 377:42 51.
24 Relapse after R-CHOP: fludarabine or bendamustine? PFS STIL trial in relapsed patients OS R-bendamustine R-fludarabine 0.8 R-bendamustine R-fludarabine BR p = p = months Rummel et al, ASH months
25 Low-dose involved field RT gives a good palliation 24 Gy Randomised trial N = Gy Indolent NHL (86% follicular) PFS 40% early stage with curative intent 24 Gy 4 Gy Response rate: 91% 81% Local progression at 2y: 7% 22% Toxicity: 4% 2% OS Hoskin et al., Lancet Oncol, 2014
26 ABMT in relapsed FL: Bart s historical comparison EFS OS Rohatiner, A. et al. J Clin Oncol; 2007
27 FL: autologous transplant in first-line GELF: n = 402 PFS OS True also for high FLIPI patients!! Sebban et al, Blood, 2006
28 Can transplant cure? Autologous: no Allogeneic: yes Hosing et al., Ann Onc 2003
29 Mini-allo transplant (RIC) for relapsed FL MDACC: OS and PFS Multicenter French study 60% chronic GvHD (36% extensive) Khouri, I. F. et al. Blood % chronic GvHD (20% extensive) Vigouroux, S. et al. Haematologica 2007
30 Idelalisib approved for R/R inhl 126 indolent lymphomas ORR 57% Gopal AK, NEJM, 2014
31 Conclusions Advanced FL is incurable: the choice of the treatment is based on cost-benefit assessment There is not a standard treatment, except grade 3(B) which certainly need R-CHOP Rituximab single agent is a good alternative to R-chemo in indolent lymphomas Transplantation is for high-risk relapse New non-chemotherapy options are coming
Challenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationFOLLICULAR LYMPHOMA. BHS course: indolent lymphoma 7 th february Ann Janssens MD, PhD Hematology UZ Leuven
FOLLICULAR LYMPHOMA BHS course: indolent lymphoma 7 th february 2015 Ann Janssens MD, PhD Hematology UZ Leuven Non Hodgkin Lymphoma Epidemiology US 1998-2011 Marginal Zone MALT 8 % Follicular 22 % 20%
More informationclinical practice guidelines
Annals of Oncology 22 (Supplement 6): vi59 vi63, 2011 doi:10.1093/annonc/mdr388 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationImmunotherapy in haematological malignancies. Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona
Immunotherapy in haematological malignancies Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Roche Celgene Mundipharma Janssen Gilead Bayer Millenium What
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationIs there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France
COSTEM Berlin September 8-11 211. Is there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France World Health Organization
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationDisease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States AJH Chadi Nabhan, 1 * Xiaolei Zhou, 2 Bann-Mo Day, 3 Keith Dawson, 3 Andrew D. Zelenetz,
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationNewly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 27 (Supplement 5): v83 v90, 2016 doi:10.1093/annonc/mdw400 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationNewly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 25 (Supplement 3): iii76 iii82, 2014 doi:10.1093/annonc/mdu200 Published online 13 August 2014 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationLYMPHOMA PROGNOSTIC INDEXES AND EMERGING NEW BIOMARKERS
Lyfe Forum of excellence 2016 What's new in Lymphoyd neoplasia? IOSI course, Bellinzona, 29-31 January 2016 LYMPHOMA PROGNOSTIC INDEXES AND EMERGING NEW BIOMARKERS DR. STEFANO LUMINARI ASSOCIATE PROFESSOR
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationPan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 3: Follicular Lymphoma
Pan-London Haemato-Oncology Clinical Guidelines Lymphoid Malignancies Part 3: Follicular Lymphoma September 2018 CONTENTS Contents 1 Introduction... 3 2 Early Diagnosis and Prevention... 3 3 Referral Pathways
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationAddress correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI
Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur
More informationAdvances in the management of follicular lymphoma
Hematology Meeting Reports 2007; 1(5):43 51 Advances in the management of follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland, Oncologia medica, Bellinzona, Switzerland Corresponding
More informationC r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S
1 Christopher R. Flowers, MD, MS Associate Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia 2 1 Anyone can get blood cancer One
More informationNuove prospettive nella terapia di prima linea
Incontro di aggiornamento sui disordini linfoproliferativi e sui protocolli della Fondazione Italiana Linfomi Torino, 24 novembre 2017 Nuove prospettive nella terapia di prima linea Luca Arcaini Department
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationPredictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
Original article Annals of Oncology 15: 1484 1489, 2004 doi:10.1093/annonc/mdh406 Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at
More informationAdvances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma
Annals of Oncology 16 (Supplement 2): ii99 ii104, 2005 doi:10.1093/annonc/mdi724 Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma M. Dreyling, C.
More informationFollicular Lymphoma. Slavisa Ninkovic 1, Christopher McNamara* 1
ARC Journal of Hematology Volume 2, Issue 1, 2017, PP 1-8 www.arcjournals.org Follicular Lymphoma Slavisa Ninkovic 1, Christopher McNamara* 1 1 Department of Hematology, University Colle ge London Hospital,
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationBendamustine: A Transversal * Chemotherapy Agent
Bendamustine: A Transversal * Chemotherapy Agent Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA *Def Cutting across two lines, intersecting
More informationTraitement de première ligne du lymphome folliculaire. F Morschhauser DES, 17 novembre,2017 Centre Hospitalier Universitaire de Lille, France
Traitement de première ligne du lymphome folliculaire F Morschhauser DES, 17 novembre,2017 Centre Hospitalier Universitaire de Lille, France What do I say to a newly diagnosed FL patient? Probability (%)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationSummary. 516 THE LANCET Vol 362 August 16, For personal use. Only reproduce with permission from The Lancet
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-hodgkin lymphoma: a randomised controlled trial K M Ardeshna, P Smith, A Norton, B W
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationTreatment: Gastric MALT lymphoma Anastasios Stathis, M.D.
Treatment: Gastric MALT lymphoma Anastasios Stathis, M.D. Phase I and Lymphoma Unit Oncology Ins6tute of Southern Switzerland Bellinzona, Switzerland Gastric MALT lymphoma MALT lymphomas: approximately
More informationObinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma
Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma 1 st Appraisal Committee meeting Background and Clinical Effectiveness Committee A Lead team John Watkins
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationIntroduction ORIGINAL ARTICLE. M. Becker 1 & B. Tschechne 2 & M. Reeb 3 & U. Schwinger 4 & H.-R. Bruch 5 & M. Frank 6 & L.
Ann Hematol (2015) 94:1553 1558 DOI 10.1007/s00277-015-2404-1 ORIGINAL ARTICLE Bendamustine as first-line treatment in patients with advanced indolent non-hodgkin lymphoma and mantle cell lymphoma in German
More informationAutologous SCT in FL No!
COSTEM 2011 Controversies in Stem Cell Transplantation and Cellular Therapies Berlin, September 10 th, 2011 Autologous SCT in FL No! Ulrich Dührsen Department of Hematology Follicular lymphoma Positioning
More informationCHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma
Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More information